Literature DB >> 25008425

Prescribing a statin to a cirrhotic patient to reduce hepatic decompensation and improve survival: impossible you say?

James H Lewis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25008425     DOI： 10.1007/s10620-014-3228-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  17 in total

1.  Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.

Authors:  Matti J Tikkanen; Rana Fayyad; Ole Faergeman; Anders G Olsson; Chuan-Chuan Wun; Rachel Laskey; John J Kastelein; Ingar Holme; Terje R Pedersen
Journal:  Int J Cardiol       Date:  2013-08-31       Impact factor: 4.164

2.  Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.

Authors:  Raj Vuppalanchi; Evegenia Teal; Naga Chalasani
Journal:  Am J Med Sci       Date:  2005-02       Impact factor: 2.378

3.  Statin use and risk of hepatocellular carcinoma.

Authors:  Shih-Wei Lai; Kuan-Fu Liao; Hsueh-Chou Lai; Chih-Hsin Muo; Fung-Chang Sung; Pei-Chun Chen
Journal:  Eur J Epidemiol       Date:  2013-05-17       Impact factor: 8.082

Review 4.  Utilization of FibroScan in clinical practice.

Authors:  Alan Bonder; Nezam Afdhal
Journal:  Curr Gastroenterol Rep       Date:  2014-02

5.  Serum alanine aminotransferase in skeletal muscle diseases.

Authors:  Rahul A Nathwani; Shireen Pais; Telfer B Reynolds; Neil Kaplowitz
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

Review 6.  Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Preet Paul Singh; Abha Goyal Singh; Mohammad Hassan Murad; William Sanchez
Journal:  Gastroenterology       Date:  2012-10-12       Impact factor: 22.682

7.  Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  James H Lewis; Mary Ellen Mortensen; Steven Zweig; Mary Jean Fusco; Jeffrey R Medoff; Rene Belder
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

8.  Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network.

Authors:  Mark W Russo; Jay H Hoofnagle; Jiezhun Gu; Robert J Fontana; Huiman Barnhart; David E Kleiner; Naga Chalasani; Herbert L Bonkovsky
Journal:  Hepatology       Date:  2014-05-13       Impact factor: 17.425

9.  Statin use is not associated with liver related mortality.

Authors:  Zahra Younoszai; Zheng Li; Maria Stepanova; Madeline Erario; Rebecca Cable; Zobair M Younossi
Journal:  Ann Hepatol       Date:  2013 Jan-2014 Feb       Impact factor: 2.400

10.  Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism.

Authors:  Naushad Ali; Heba Allam; Ted Bader; Randal May; Kanthesh M Basalingappa; William L Berry; Parthasarathy Chandrakesan; Dongfeng Qu; Nathaniel Weygant; Michael S Bronze; Shahid Umar; Ralf Janknecht; Sripathi M Sureban; Mark Huycke; Courtney W Houchen
Journal:  PLoS One       Date:  2013-11-19       Impact factor: 3.240
View more
  1 in total

Review 1.  Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.

Authors:  Jonathan G Stine; James H Lewis
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-25       Impact factor: 3.869
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.